title: Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism.
abstract: Multiple myeloma (MM) is a malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. Despite extensive efforts to design drugs targeting tumoral cells and their microenvironment, MM remains an incurable disease for which new therapeutic strategies are needed. We demonstrated here that antiestrogens (AEs) belonging to selective estrogen receptor modulators family induce a caspase-dependent apoptosis and trigger a protective autophagy. Autophagy was recognized by monodansylcadaverin staining, detection of autophagosomes by electronic microscopy, and detection of the cleaved form of the microtubule-associated protein light chain 3. Moreover, autophagy was inhibited by drugs such as bafilomycin A1 and 3-methyladenosine. Autophagy was mediated by the binding of AEs to a class of receptors called the antiestrogen binding site (AEBS) different from the classical estrogen nuclear receptors. The binding of specific ligands to the AEBS was accompanied by alteration of cholesterol metabolism and in particular accumulation of sterols: zymostenol or desmosterol depending on the ligand. This was due to the inhibition of the cholesterol-5,6-epoxide hydrolase activity borne by the AEBS. We further showed that the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway mediated autophagy signaling. Moreover, AEBS ligands restored sensitivity to dexamethasone in resistant MM cells. Since we showed previously that AEs arrest MM tumor growth in xenografted mice, we propose that AEBS ligands may have a potent antimyeloma activity alone or in combination with drugs used in clinic.
authors: Normandie University, UNICAEN EA4652, Caen, France.
authors: Brigitte
authors: B
authors: Sola
authors: Marc
authors: M
authors: Poirot
authors: Philippe
authors: P
authors: de Medina
authors: Sophie
authors: S
authors: Bustany
authors: Véronique
authors: V
authors: Marsaud
authors: Sandrine
authors: S
authors: Silvente-Poirot
authors: Jack-Michel
authors: JM
authors: Renoir
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001343:Autophagy / Q000187:drug effects; D001665:Binding Sites; D045744:Cell Line, Tumor; D002784:Cholesterol / Q000378:metabolism*; D020847:Estrogen Receptor Modulators / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology
chemical_list: D020847:Estrogen Receptor Modulators; D008024:Ligands; D002784:Cholesterol
references: Curr Opin Pharmacol. 2012 Dec;12(6):696-703
references: 22917620
references: J Biol Chem. 2000 Jan 14;275(2):992-8
references: 10625637
references: Cell Death Differ. 2009 Oct;16(10):1372-84
references: 19521424
references: Biochim Biophys Acta. 2009 Jul;1791(7):671-8
references: 19232397
references: Clin Cancer Res. 2005 Mar 15;11(6):2345-54
references: 15788686
references: Autophagy. 2012 Apr;8(4):445-544
references: 22966490
references: Nat Rev Clin Oncol. 2012 Feb 21;9(3):135-43
references: 22349016
references: Curr Biol. 2009 Dec 1;19(22):R1046-52
references: 19948145
references: Mol Pharmacol. 2006 May;69(5):1615-23
references: 16497877
references: Leuk Res. 2010 Nov;34(11):1533-8
references: 20667592
references: Mol Cancer Ther. 2010 Apr;9(4):963-75
references: 20371718
references: Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13520-5
references: 20615952
references: Biochem Pharmacol. 2013 Jul 1;86(1):175-89
references: 23500540
references: PLoS One. 2011;6(10):e25820
references: 22028791
references: Carcinogenesis. 2009 Apr;30(4):575-9
references: 19168586
references: Nat Rev Cancer. 2007 Jan;7(1):46-53
references: 17186017
references: Cancer Res. 2000 Mar 1;60(5):1434-41
references: 10728710
references: Nat Rev Cancer. 2009 Sep;9(9):631-43
references: 19701242
references: Clin Cancer Res. 2011 May 15;17(10):3248-58
references: 21288924
references: Trends Immunol. 2009 Jun;30(6):277-85
references: 19447676
references: EMBO Rep. 2013 Mar 1;14(3):242-51
references: 23399656
references: Pharm Res. 2010 Feb;27(2):327-39
references: 20033476
references: Cell Death Differ. 2012 Jan;19(1):107-20
references: 21760595
references: Curr Opin Pharmacol. 2010 Dec;10(6):620-8
references: 20926342
references: Mol Cancer Ther. 2008 Dec;7(12):3707-18
references: 19074846
references: Haematologica. 2011 Apr;96(4):574-82
references: 21173094
references: Mol Pharmacol. 2010 Dec;78(6):1046-58
references: 20837678
references: PLoS One. 2010 Jan 06;5(1):e8604
references: 20062536
references: J Biol Chem. 2009 Sep 25;284(39):26816-30
references: 19648108
references: Oncogene. 2002 Sep 26;21(43):6587-97
references: 12242656
references: Leukemia. 2007 Mar;21(3):541-9
references: 17252022
references: Cell Cycle. 2010 Sep 1;9(17):3470-8
references: 20703092
references: Lancet. 2009 Jul 25;374(9686):324-39
references: 19541364
references: Blood. 1998 Sep 1;92(5):1749-57
references: 9716605
references: Cell Death Differ. 2013 Jan;20(1):3-11
references: 22595754
references: Biochem Pharmacol. 2013 Feb 15;85(4):449-65
references: 23103568
references: Autophagy. 2012 Dec;8(12):1873-4
references: 22995770
references: FEBS Lett. 2010 Jul 2;584(13):2731-9
references: 20416299
references: Int J Cancer. 2008 May 1;122(9):2130-41
references: 18183592
references: Blood. 2012 Oct 25;120(17):3519-29
references: 22955917
references: Leukemia. 2009 Dec;23(12):2210-21
references: 19798094
references: Bioorg Med Chem. 2000 Aug;8(8):2007-16
references: 11003145
references: Mol Cancer Ther. 2009 Jul;8(7):1974-84
references: 19509276
references: J Biol Chem. 2004 Aug 6;279(32):34048-61
references: 15175332
references: J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):67-78
references: 16753295